← Leaderboards
Luisa Escobar Hoyos
Sloan-Kettering Inst Can Research
$5,863,708
Attributed
$5,863,708
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2018–25$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,863,708 · 4
By mechanism
DP2$2,512,500 · 1
R01$2,406,506 · 1
R00$740,588 · 1
K99$204,114 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Scott W Lowe$63,222,126
- Samuel Singer$8,089,401
- Michael Kharas$18,485,709
- Xiang Zhang$12,735,442
- Ross L Levine$31,715,816
Others in their field
Other Emerging Leaders on “Rna Splicing”
- William H. Peranteau · Children'S Hosp Of Philadelphia$7,624,302
- Aaron D Finke · Cornell University$5,853,775
- Sebastian Kadener · Brandeis University$5,664,050
- Justin B. Kinney · Cold Spring Harbor Laboratory$5,625,506
- Richard Edward Gillilan · Cornell University$5,582,265
- Gudrun Stengel · Alida Biosciences, Inc.$5,292,779
Research focus
Rna SplicingResponseTumorGenetic TranscriptionMutationMalignant Neoplasm Of PancreasMutantProtein IsoformsPancreatic Cancer PatientsTp53 GeneNovel TherapeuticsOncoproteinsPancreatic Ductal AdenocarcinomaPathogenesisMolecular SubtypesKras2 GeneSmall Molecule InhibitorIn VitroIn VivoSignal TransductionMessenger RnaMolecularGain Of FunctionSpliceosomes
Grant awards (13)
Unleashing T-cell anti-tumor response through repair of altered RNA splicing and antigen mimicry recognition$1,005,000
DP2 · FY2025 · CA · contact PI
Understanding and targeting mutant splicing factors in pancreatic cancer$738,594
R01 · FY2025 · CA · contact PI
Understanding and targeting mutant splicing factors in pancreatic cancer$327,677
R01 · FY2025 · CA · contact PI
Understanding and targeting mutant splicing factors in pancreatic cancer$357,313
R01 · FY2024 · CA · contact PI
Understanding and targeting mutant splicing factors in pancreatic cancer$155,616
R01 · FY2024 · CA · contact PI
Understanding and targeting mutant splicing factors in pancreatic cancer$396,332
R01 · FY2023 · CA · contact PI
Unleashing T-cell anti-tumor response through repair of altered RNA splicing and antigen mimicry recognition$1,507,500
DP2 · FY2022 · CA · contact PI
Understanding and targeting mutant splicing factors in pancreatic cancer$430,974
R01 · FY2022 · CA · contact PI
Altered mRNA splicing dependent on mutant p53 identifies novel therapeutic vulnerability in pancreatic cancer$245,749
R00 · FY2022 · CA · contact PI
Altered mRNA splicing dependent on mutant p53 identifies novel therapeutic vulnerability in pancreatic cancer$245,839
R00 · FY2021 · CA · contact PI
Altered mRNA splicing dependent on mutant p53 identifies novel therapeutic vulnerability in pancreatic cancer$249,000
R00 · FY2020 · CA · contact PI
Altered mRNA splicing dependent on mutant p53 identifies novel therapeutic vulnerability in pancreatic cancer$102,057
K99 · FY2019 · CA · contact PI
Altered mRNA splicing dependent on mutant p53 identifies novel therapeutic vulnerability in pancreatic cancer$102,057
K99 · FY2018 · CA · contact PI